Lucid Diagnostics (LUCD) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Lucid Diagnostics is expected to announce its Q2 2025 earnings on August 13th, projecting earnings of ($0.09) per share and revenue of $1.15 million.
• The company's stock opened at $1.00, with a market cap of $108.19 million and a 12-month trading range between $0.73 and $1.80.
• Analyst ratings reflect mixed sentiment with one "sell," four "buy," and one "strong buy," leading to a consensus rating of "Moderate Buy" and a consensus price target of $3.55.

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $1.15 million for the quarter.

Lucid Diagnostics Stock Performance

LUCD traded down $0.01 during trading on Thursday, hitting $0.98. 521,660 shares of the company's stock were exchanged, compared to its average volume of 927,868. The business's 50 day moving average is $1.16 and its two-hundred day moving average is $1.25. Lucid Diagnostics has a fifty-two week low of $0.73 and a fifty-two week high of $1.80.

Hedge Funds Weigh In On Lucid Diagnostics

An institutional investor recently bought a new position in Lucid Diagnostics stock. Cubist Systematic Strategies LLC acquired a new stake in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 26,048 shares of the company's stock, valued at approximately $39,000. 74.01% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $2.00 price target on shares of Lucid Diagnostics in a report on Thursday, May 15th. Ascendiant Capital Markets boosted their price target on shares of Lucid Diagnostics from $7.50 to $7.75 and gave the company a "buy" rating in a research report on Friday, June 6th. Needham & Company LLC reiterated a "buy" rating and issued a $3.00 price objective on shares of Lucid Diagnostics in a research report on Wednesday, July 16th. Finally, Wall Street Zen cut Lucid Diagnostics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $3.55.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.